(Page 2 of 2)
future payments. River Vision Development was acquired by Horizon Pharma for $145 million a week ago.
—Seattle’s Genoa Pharmaceuticals has raised a $62 million Series A round and hired local biotech veteran Bruce Montgomery to take the CEO seat and lead the firm through Phase 2 studies of its inhaled version of pirfenidone, a treatment for deadly lung scarring. Genoa is aiming for fewer side effects than the pill version, approved in 2014 and now marketed by Roche.
—Vifor Pharma made a $50 million equity investment in Akebia Therapeutics (NASDAQ: AKBA) at $14 per share. The deal gives Akebia license to sell its anemia pill vadadustat, upon FDA approval, at Fresenius Medical Care dialysis clinics in the U.S. Vadadustat and rival roxadustat from Fibrogen are both in Phase 3 testing.
—Xconomy held its annual “What’s Hot in Boston Biotech” event last week, and this week we circled back with photos and takeaways from the event, including thoughts on immigration, diversity, cancer research, and patient advocacy.
—Alex Lash and Frank Vinluan contributed to this report.